SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-065311
Filing Date
2023-03-09
Accepted
2023-03-09 07:36:53
Documents
14
Period of Report
2023-03-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d367644d8k.htm   iXBRL 8-K 25887
2 EX-99.1 d367644dex991.htm EX-99.1 77815
6 GRAPHIC g367644dsp5a.jpg GRAPHIC 3287
  Complete submission text file 0001193125-23-065311.txt   240275

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA akba-20230309.xsd EX-101.SCH 2834
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20230309_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20230309_pre.xml EX-101.PRE 10801
8 EXTRACTED XBRL INSTANCE DOCUMENT d367644d8k_htm.xml XML 3279
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 23718213
SIC: 2834 Pharmaceutical Preparations